Disseminated intravascular coagulation (ISTH score) is a complex, acquired systemic syndrome defined by widespread intravascular activation of coagulation pathways, loss of localized regulatory control, and simultaneous impairment of fibrinolysis 1, 2. This pathological cascade precipitates extensive microvascular fibrin deposition, culminating in ischemic end-organ dysfunction, while concurrently depleting circulating platelets and clotting factors to induce severe, diffuse hemorrhagic complications 3, 4. Rather than existing as a primary disease entity, DIC represents a catastrophic downstream manifestation of diverse systemic insults, most notably severe infection, major tissue trauma, obstetric catastrophes, and malignancy 5, 6. Accurate and timely diagnosis relies on integrating routine global hemostatic assays into validated scoring frameworks, such as the International Society on Thrombosis and Haemostasis (ISTH) overt DIC algorithm, to guide prompt source control and individualized supportive care 2, 7.

1. Etiology & Risk Factors

  • Infectious Insults: Severe bacterial sepsis (both Gram-negative endotoxins and Gram-positive peptidoglycans), severe viral infections, rickettsial disease, and overwhelming parasitic infestations like malaria 1, 5.
  • Obstetric Emergencies: Amniotic fluid embolism, placental abruption, eclampsia, HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count), and retained dead fetus syndrome, which introduce massive amounts of tissue factor into the maternal circulation 3, 4.
  • Malignancies: Acute promyelocytic leukemia (APL) characterized by the release of procoagulant molecules (annexin II and cancer procoagulant), as well as advanced solid tumors including adenocarcinoma of the pancreas, prostate, stomach, and lung 4, 5.
  • Trauma & Tissue Injury: Severe polytrauma, extensive burns, catastrophic neurotrauma, and heat stroke, which trigger massive tissue factor liberation and endothelial disruption 5, 6.
  • Vascular Abnormalities: Large aortic aneurysms and giant hemangiomas (Kasabach-Merritt phenomenon) promoting local stasis and consumption of hemostatic elements 1, 3.
  • Miscellaneous Triggers: Severe toxic or venomous snake bites (e.g., vipers), severe acute transfusion reactions, massive hepatic failure, and post-cardiopulmonary bypass complications 1, 4.

2. Pathophysiology

The pathogenesis of disseminated intravascular coagulation centers on the systemic, dysregulated release of procoagulant mediators into the vascular space, overwhelmingly driven by tissue factor (TF) upregulation on monocytes and damaged endothelial cells 5, 7. In response to inflammatory cytokines such as tumor necrosis factor-alpha (TNF-$\alpha$) and interleukins (IL-1, IL-6), circulating factor VIIa binds exposed tissue factor, initiating the extrinsic coagulation pathway and generating massive quantities of thrombin 5. Normally, physiological anticoagulant mechanisms—including the antithrombin system, protein C-protein S pathway, and tissue factor pathway inhibitor (TFPI)—mitigate localized clotting. In DIC, these regulatory pathways are profoundly impaired; antithrombin is consumed and degraded by neutrophil elastase, while endothelial thrombomodulin expression is downregulated by inflammatory cytokines, crippling the activation of protein C 5, 7. Simultaneously, fibrinolytic homeostasis is severely disrupted. Initial activation of plasminogen is rapidly overwhelmed by a massive, sustained hepatic and endothelial release of plasminogen activator inhibitor 1 (PAI-1), resulting in a suppressed fibrinolytic state that protects microvascular thrombi from dissolution 5, 7. The unhindered accumulation of intravascular fibrin microthrombi obstructs capillary blood flow across vital organs, precipitating tissue ischemia, cellular hypoxia, and ultimately multi-organ dysfunction syndrome (MODS) 6, 7. Concurrently, the relentless consumption of circulating platelets, fibrinogen, and coagulation factors II, V, and VIII converts the system into a consumptive coagulopathy, predisposing the patient to spontaneous, life-threatening hemorrhage from mucosal surfaces, surgical wounds, and venipuncture sites 3, 4.

Disseminated intravascular coagulation (ISTH score) — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Systemic release of tissue factor via sepsis, trauma, or obstetric complications 2 Cellular / Pathophysiological Cascade Unchecked thrombin generation coupled with impaired natural anticoagulants and suppressed fibrinolysis 3 Target Organ / Structural Change Microvascular fibrin deposition obstructing capillary beds across vital organs 4 Hallmark Clinical & Diagnostic Manifestation Consumption of platelets and clotting factors leading to simultaneous thrombosis and oozing hemorrhage 5 Complications if Untreated & Therapeutic Target Multi-organ failure and exsanguination requiring prompt underlying trigger elimination and blood component resuscitation

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients typically present with an acute, severe underlying medical illness (e.g., septic shock, postpartum hemorrhage, polytrauma). Cardinal symptoms include sudden, unprovoked bleeding from multiple anatomical sites, progressive shortness of breath secondary to pulmonary microthrombi or hemorrhage, oliguria or anuria reflecting acute kidney injury, and altered mental status due to cerebral hypoperfusion or micro-infarctions 3, 4, 7.
  • Physical Examination & Named Clinical Signs: Examination reveals diffuse mucocutaneous bleeding, persistent oozing from intravascular catheter and venepuncture sites, large ecchymoses, and petechiae 3, 7. In fulminant cases, widespread microvascular thrombosis leads to acral cyanosis, dry gangrene of the digits, and rapidly progressive purpura fulminans 1, 3. Hemodynamic instability, tachycardia, tachypnea, and hypotension frequently indicate concurrent septic or hypovolemic shock 5, 6.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationISTH Overt DIC Scoring Algorithm (score $\ge$ 5 points), synthesized from platelet count, PT prolongation, fibrinogen level, and fibrin-related markers 2, 5.
Laboratory PanelThrombocytopenia (platelets typically $<100 \times 10^9/\text{L}$ or rapidly falling); prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT); markedly elevated D-dimer and fibrin degradation products (FDPs); depressed plasma fibrinogen ($<1.0\text{–}1.5\text{ g/L}$) 1, 3.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography may demonstrate patchy infiltrates or pulmonary hemorrhage; abdominal imaging can reveal renal cortical necrosis, splenic infarctions, or hepatic ischemia; cranial imaging may show multifocal ischemic or hemorrhagic strokes 4, 7.
ECG / Histopathology / ProceduralElectrocardiogram may show non-specific ST-T wave changes reflecting myocardial microthrombi; peripheral blood smear demonstrates classic schistocytes (fragmented red blood cells resulting from shear stress across fibrin strands) alongside marked thrombocytopenia 1, 3.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Platelet Count ($10^9/\text{L}$)$>100$ (0 points); $<100$ (1 point); $<50$ (2 points) 1, 5.
Elevated Fibrin-Related Markers (e.g., D-dimer, FDP)No increase (0 points); moderate increase (2 points); strong increase (3 points) 2, 5.
Prolonged Prothrombin Time (PT / INR)$<3\text{ seconds over reference}$ (0 points); $3\text{ to }<6\text{ seconds over reference}$ (1 point); $\ge 6\text{ seconds over reference}$ (2 points) 1, 5.
Fibrinogen Level (g/L)$>1.0\text{ g/L}$ (0 points); $<1.0\text{ g/L}$ (1 point) 1, 5.
Diagnostic Threshold & InterpretationA cumulative score $\ge 5$ indicates overt DIC (compatible with serial daily re-evaluation); a score $<5$ suggests non-overt DIC, mandating close monitoring and repeat testing within 24 hours 2, 5.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Thrombotic Thrombocytopenic Purpura (TTP)Characterized by severe ADAMTS13 deficiency ($<10\%$), prominent microangiopathic hemolytic anemia with numerous schistocytes, profound thrombocytopenia, and fluctuating neurological symptoms, but with normal PT, aPTT, and fibrinogen levels 1, 4.
Hemolytic Uremic Syndrome (HUS)Classically triggered by Shiga toxin-producing E. coli, presenting with microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, maintaining normal coagulation parameters (PT, aPTT, fibrinogen) 3, 5.
Liver Failure / CirrhosisMarked synthesis failure of multiple clotting factors leading to prolonged PT and aPTT, accompanied by thrombocytopenia secondary to hypersplenism; however, fibrinogen synthesis is typically impaired without the explosive systemic thrombin generation and elevated D-dimer characteristic of DIC 4, 6.
Vitamin K Deficiency / Warfarin ToxicityProlonged PT and aPTT due to impaired gamma-carboxylation of vitamin K-dependent factors (II, VII, IX, X), but associated with a normal platelet count and normal fibrinogen levels, without microvascular thrombosis 1, 3.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Secure airway, breathing, and circulation. Aggressively manage hemodynamic instability with fluid resuscitation, vasopressors for septic shock, and immediate correction of severe hypoxia and acidosis 3, 4.
  • First-Line Medical / Pharmacological Therapy: The cornerstone of DIC management is the rapid identification and elimination of the underlying trigger (e.g., broad-spectrum intravenous antibiotics for sepsis, emergency delivery or uterine evacuation for obstetric catastrophes, or induction chemotherapy for acute promyelocytic leukemia) 3, 4, 5.

    Supportive blood component therapy must be tailored to clinical bleeding and laboratory parameters:
    • Platelets: Transfuse to maintain a target platelet count $>50 \times 10^9/\text{L}$ in actively bleeding patients or those at high risk of hemorrhage, and $>20 \times 10^9/\text{L}$ in non-bleeding patients with severe consumptive risk 3, 4.
    • Fresh Frozen Plasma (FFP): Administer at an initial dose of $15\text{ mL/kg}$ to correct prolonged PT and aPTT in patients with active bleeding or prior to invasive procedures 3, 4.
    • Cryoprecipitate / Fibrinogen Concentrate: Administer if plasma fibrinogen levels fall below $1.5\text{ g/L}$ despite FFP repletion, targeting a safe functional fibrinogen level $>1.5\text{ to }2.0\text{ g/L}$ 3, 4.

    Anticoagulation with therapeutic or prophylactic doses of heparin (unfractionated or low-molecular-weight heparin) may be considered in patients with predominant thrombotic manifestations (e.g., purpura fulminans, APL-associated DIC, or extensive large-vessel thrombosis), provided there is no active major bleeding 4, 5.
  • Surgical / Interventional Indications: Urgent surgical source control for septic foci, operative evacuation of hematomas, surgical management of placental abruption, or embolization procedures for intractable postpartum or traumatic hemorrhage 3, 6.

8. Complications & Prognosis

  • Acute Complications: Exsanguinating hemorrhage from surgical wounds and mucosal sites, multi-organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), acute kidney injury requiring renal replacement therapy, adrenal hemorrhage (Waterhouse-Friderichsen syndrome), and extensive skin necrosis or digital gangrene requiring amputation 3, 5, 7.
  • Prognosis & Mortality: Prognosis is inextricably linked to the reversibility of the underlying precipitating condition 3, 4. While mild compensated forms carry a favorable outlook with prompt treatment, overt decompensated DIC associated with severe sepsis, trauma, or multiorgan failure carries high morbidity and mortality rates exceeding $40\text{–}60\%$ 5, 7.